G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Flo...
Dyadic International, Inc. is a global biotechn...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...
Magenta Therapeutics is a clinical-stage biotec...
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
Vericel is a leader in advanced therapies for the sports medicine and severe burn ...
Vericel is a leader in advanced therapies for t...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Bellicum Pharmaceuticals is a clinical-stage bi...
Join the National Investor Network and get the latest information with your interests in mind.